FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots

WASHINGTON (AP) — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing uncertainty about updates to other vaccines, too.